Glaukos Corp
Closed
SectorHealthcare
137.54 2.25
Overview
Share price change
24h
Min
131.81
Max
140.58
Income | 114M -20M |
|---|---|
Sales | 7.5M 151M |
EPS | -0.18 |
Profit margin | -13.139 |
Employees | 1,094 |
EBITDA | 124M -5.3M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +17.59% upside |
Next Earnings | 29 Jul 2026 |
|---|
Market Cap | 719M 7.9B |
|---|---|
Previous open | 135.29 |
Previous close | 137.54 |
News Sentiment
By Acuity
21%
79%
45 / 342 Healthcare
Glaukos Corp Chart
Past performance is not a reliable indicator of future results.
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.